SCHEMBL21553064

SCHEMBL21553064

CN1CCN(c2nc(CCC=O)cn(-c3ccc(S(=O)(=O)N(C)C)cc3)c2=O)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.39
JAK3 P52333 1/20 0.39
PTK2 Q05397 1/20 0.39
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
ATM Q13315 1/20 0.35
ALDH1A1 P00352 3/20 0.35
HTR2C P28335 3/20 0.35
HTR6 P50406 3/20 0.35
HTR1A P08908 2/20 0.35
HTR2A P28223 2/20 0.35
HTR7 P34969 2/20 0.35
DRD3 P35462 2/20 0.35
TP53 P04637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ABCB11 O95342 1/20 0.35
ADRA2A P08913 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21553127 0.89 SMN1; SMN2 (0.37) MEN1KMT2AALDH1A1TP53LMNA
SCHEMBL21552957 0.86 JAK2 (0.41) JAK2JAK3PTK2MEN1KMT2A
SCHEMBL23258181 0.86 JAK2 (0.39) JAK2JAK3PTK2MEN1KMT2A
SCHEMBL21564620 0.84 GPR119 (0.44) JAK2JAK3PTK2MEN1KMT2A
SCHEMBL21553000 0.83 MEN1 (0.40) MEN1KMT2AALDH1A1HTR6TP53
SCHEMBL21552887 0.82 L3MBTL1 (0.42) JAK2JAK3PTK2KMT2AATM
SCHEMBL21552883 0.79 SYK (0.37) MEN1KMT2AALDH1A1KDM4EUSP2
SCHEMBL21553092 0.78 NOTUM (0.34) MEN1KMT2AALDH1A1HTR3AUSP2
SCHEMBL21564608 0.78 AKR1C3 (0.41) JAK2JAK3PTK2ALDH1A1GHSR
SCHEMBL21553043 0.77 PTGS2 (0.35) ALDH1A1KDM4EADORA2ALMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790867-B1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2024-03-27 EP disclosed
US-11932629-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
CN-112513020-B KDM1A inhibitors for the treatment of diseases 伊美格生物科学公司 2024-02-23 CN disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
EP-3790867-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2021-03-17 EP disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932629-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A JAK2 704/4885JAK3 1253/4885PTK2 2940/4885
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A JAK2 704/4885JAK3 1253/4885PTK2 2940/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A JAK2 590/4885JAK3 1041/4885PTK2 2648/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A JAK2 704/4885JAK3 1253/4885PTK2 2940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.